The DOI matches its Crossref record; 87 of the 87 references it cites were found in a registry or an index.
Innate immune and inflammatory responses to SARS-CoV-2: Implications for COVID-19
Open accessAbstract
COVID-19 can result in severe disease characterized by significant immunopathology that is spurred by an exuberant, yet dysregulated, innate immune response with a poor adaptive response. A limited and delayed interferon I (IFN-I) and IFN-III response results in exacerbated proinflammatory cytokine production and in extensive cellular infiltrates in the respiratory tract, resulting in lung pathology. The development of effective therapeutics for patients with severe COVID-19 depends on our understanding of the pathological elements of this unbalanced innate immune response. Here, we review the mechanisms by which SARS-CoV-2 both activates and antagonizes the IFN and inflammatory response following infection, how a dysregulated cytokine and cellular response contributes to immune-mediated pathology in COVID-19, and therapeutic strategies that target elements of the innate response.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED: 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study
Huang, C., Huang, L., Wang, Y., Li, X., Ren, L., Gu, X., Kang, L., Guo, L., Liu, M., Zhou, X., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32656-8 · Cited by 4,084
RetractedClinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30183-5 · Cited by 48,884
Zhou, F., Yu, T., Du, R., Fan, G., Liu, Y., Liu, Z., Xiang, J., Wang, Y., Song, B., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30566-3 · Cited by 27,263
A pneumonia outbreak associated with a new coronavirus of probable bat origin
Zhou, P., Yang, X.-L., Wang, X.-G., Hu, B., Zhang, L., Zhang, W., Si, H.-R., Zhu, Y., Li, B., Huang, C.-L., et al. (2020) · Nature · doi:10.1038/s41586-020-2012-7 · Cited by 21,969
Dexamethasone in Hospitalized Patients with Covid-19
The RECOVERY Collaborative Group (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2021436 · Cited by 11,477
Pathological findings of COVID-19 associated with acute respiratory distress syndrome
Xu, Z., Shi, L., Wang, Y., Zhang, J., Huang, L., Zhang, C., Liu, S., Zhao, P., Liu, H., Zhu, L., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30076-x · Cited by 8,545
Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19
Ackermann, M., Verleden, S. E., Kuehnel, M., Haverich, A., Welte, T., Laenger, F., Vanstapel, A., Werlein, C., Stark, H., Tzankov, A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2015432 · Cited by 5,613
Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19
Blanco-Melo, D., Nilsson-Payant, B. E., Liu, W.-C., Uhl, S., Hoagland, D., Møller, R., Jordan, T. X., Oishi, K., Panis, M., Sachs, D., et al. (2020) · Cell · doi:10.1016/j.cell.2020.04.026 · Cited by 4,222
Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients
Hadjadj, J., Yatim, N., Barnabei, L., Corneau, A., Boussier, J., Smith, N., Péré, H., Charbit, B., Bondet, V., Chenevier-Gobeaux, C., et al. (2020) · Science · doi:10.1126/science.abc6027 · Cited by 2,984
Autoantibodies against type I IFNs in patients with life-threatening COVID-19
Bastard, P., Rosen, L. B., Zhang, Q., Michailidis, E., Hoffmann, H.-H., Zhang, Y., Dorgham, K., Philippot, Q., Rosain, J., Béziat, V., et al. (2020) · Science · doi:10.1126/science.abd4585 · Cited by 2,662
Inborn errors of type I IFN immunity in patients with life-threatening COVID-19
Zhang, Q., Bastard, P., Liu, Z., Le Pen, J., Moncada-Velez, M., Chen, J., Ogishi, M., Sabli, I. K. D., Hodeib, S., Korol, C., et al. (2020) · Science · doi:10.1126/science.abd4570 · Cited by 2,229
Longitudinal analyses reveal immunological misfiring in severe COVID-19
Lucas, C., Wong, P., Klein, J., Castro, T. B. R., Silva, J., Sundaram, M., Ellingson, M. K., Mao, T., Oh, J. E., Israelow, B., et al. (2020) · Nature · doi:10.1038/s41586-020-2588-y · Cited by 2,074
Interleukin-6 receptor antagonists in critically ill patients with Covid-19.
The REMAP-CAP Investigators (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2100433 · Cited by 1,962
Karki, R., Sharma, B. R., Tuladhar, S., Williams, E. P., Zalduondo, L., Samir, P., Zheng, M., Sundaram, B., Banoth, B., Malireddi, R. K. S., et al. (2021) · Cell · doi:10.1016/j.cell.2020.11.025 · Cited by 1,734
Liu, J., Li, S., Liu, J., Liang, B., Wang, X., Wang, H., Li, W., Tong, Q., Yi, J., Zhao, L., et al. (2020) · eBioMedicine · doi:10.1016/j.ebiom.2020.102763 · Cited by 1,702
Hung, I. F.-N., Lung, K.-C., Tso, E. Y.-K., Liu, R., Chung, T. W.-H., Chu, M.-Y., Ng, Y.-Y., Lo, J., Chan, J., Tam, A. R., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31042-4 · Cited by 1,455
Channappanavar, R., Fehr, A. R., Vijay, R., Mack, M., Zhao, J., Meyerholz, D. K., & Perlman, S. (2016) · Cell Host & Microbe · doi:10.1016/j.chom.2016.01.007 · Cited by 1,419
Self-citationGenetic mechanisms of critical illness in COVID-19
The GenOMICC Investigators, Pairo-Castineira, E., The ISARIC4C Investigators, Initiative, T. C.-1. H. G., 23andMe Investigators, BRACOVID Investigators, Gen-COVID Investigators, Clohisey, S., Klaric, L., Bretherick, A. D., et al. (2021) · Nature · doi:10.1038/s41586-020-03065-y · Cited by 1,365
Pathogenic T-cells and inflammatory monocytes incite inflammatory storms in severe COVID-19 patients
Zhou, Y., Fu, B., Zheng, X., Wang, D., Zhao, C., Qi, Y., Sun, R., Tian, Z., Xu, X., & Wei, H. (2020) · National Science Review · doi:10.1093/nsr/nwaa041 · Cited by 1,295
Tomazini, B. M., Maia, I. S., Cavalcanti, A. B., Berwanger, O., Rosa, R. G., Veiga, V. C., Avezum, A., Lopes, R. D., Bueno, F. R., Silva, M. V. A. O., et al. (2020) · JAMA · doi:10.1001/jama.2020.17021 · Cited by 1,241
Shared and Distinct Functions of Type I and Type III Interferons
Lazear, H. M., Schoggins, J. W., & Diamond, M. S. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.025 · Cited by 1,138
Lung pathology of fatal severe acute respiratory syndrome
Nicholls, J. M., Poon, L. L., Lee, K. C., Ng, W. F., Lai, S. T., Leung, C. Y., Chu, C. M., Hui, P. K., Mak, K. L., Lim, W., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13413-7 · Cited by 1,076
Activation and evasion of type I interferon responses by SARS-CoV-2
Lei, X., Dong, X., Ma, R., Wang, W., Xiao, X., Tian, Z., Wang, C., Wang, Y., Li, L., Ren, L., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17665-9 · Cited by 980
Evasion of Type I Interferon by SARS-CoV-2
Xia, H., Cao, Z., Xie, X., Zhang, X., Chen, J. Y.-C., Wang, H., Menachery, V. D., Rajsbaum, R., & Shi, P.-Y. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108234 · Cited by 957
Pathological study of the 2019 novel coronavirus disease (COVID-19) through postmortem core biopsies
Tian, S., Xiong, Y., Liu, H., Niu, L., Guo, J., Liao, M., & Xiao, S.-Y. (2020) · Modern Pathology · doi:10.1038/s41379-020-0536-x · Cited by 948
SARS-CoV-2–triggered neutrophil extracellular traps mediate COVID-19 pathology
Veras, F. P., Pontelli, M. C., Silva, C. M., Toller-Kawahisa, J. E., de Lima, M., Nascimento, D. C., Schneider, A. H., Caetité, D., Tavares, L. A., Paiva, I. M., et al. (2020) · Journal of Experimental Medicine · doi:10.1084/jem.20201129 · Cited by 933
The Writing Committee for the REMAP-CAP Investigators, Angus, D. C., Derde, L., Al-Beidh, F., Annane, D., Arabi, Y., Beane, A., van Bentum-Puijk, W., Berry, L., Bhimani, Z., et al. (2020) · JAMA · doi:10.1001/jama.2020.17022 · Cited by 855
Leisman, D. E., Ronner, L., Pinotti, R., Taylor, M. D., Sinha, P., Calfee, C. S., Hirayama, A. V., Mastroiani, F., Turtle, C. J., Harhay, M. O., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30404-5 · Cited by 855
COVID-19 Autopsies, Oklahoma, USA
Barton, L. M., Duval, E. J., Stroberg, E., Ghosh, S., & Mukhopadhyay, S. (2020) · American Journal of Clinical Pathology · doi:10.1093/ajcp/aqaa062 · Cited by 839
Rodrigues, T. S., de Sá, K. S. G., Ishimoto, A. Y., Becerra, A., Oliveira, S., Almeida, L., Gonçalves, A. V., Perucello, D. B., Andrade, W. A., Castro, R., et al. (2021) · Journal of Experimental Medicine · doi:10.1084/jem.20201707 · Cited by 839
SARS-CoV-2 infection protects against rechallenge in rhesus macaques
Chandrashekar, A., Liu, J., Martinot, A. J., McMahan, K., Mercado, N. B., Peter, L., Tostanoski, L. H., Yu, J., Maliga, Z., Nekorchuk, M., et al. (2020) · Science · doi:10.1126/science.abc4776 · Cited by 816
Muñoz-Fontela, C., Dowling, W. E., Funnell, S. G. P., Gsell, P.-S., Riveros-Balta, A. X., Albrecht, R. A., Andersen, H., Baric, R. S., Carroll, M. W., Cavaleri, M., et al. (2020) · Nature · doi:10.1038/s41586-020-2787-6 · Cited by 798
Self-citationCircuits between infected macrophages and T cells in SARS-CoV-2 pneumonia
Grant, R. A., Morales-Nebreda, L., Markov, N. S., Swaminathan, S., Querrey, M., Guzman, E. R., Abbott, D. A., Donnelly, H. K., Donayre, A., Goldberg, I. A., et al. (2021) · Nature · doi:10.1038/s41586-020-03148-w · Cited by 727
The dual nature of type I and type II interferons
Lee, A. J., & Ashkar, A. A. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02061 · Cited by 690
A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures
Dinnon, K. H., Leist, S. R., Schäfer, A., Edwards, C. E., Martinez, D. R., Montgomery, S. A., West, A., Yount, B. L., Hou, Y. J., Adams, L. E., et al. (2020) · Nature · doi:10.1038/s41586-020-2708-8 · Cited by 675
Chu, H., Chan, J. F.-W., Wang, Y., Yuen, T. T.-T., Chai, Y., Hou, Y., Shuai, H., Yang, D., Hu, B., Huang, X., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa410 · Cited by 667
A Mouse Model of SARS-CoV-2 Infection and Pathogenesis
Sun, S.-H., Chen, Q., Gu, H.-J., Yang, G., Wang, Y.-X., Huang, X.-Y., Liu, S.-S., Zhang, N.-N., Li, X.-F., Xiong, R., et al. (2020) · Cell Host & Microbe · doi:10.1016/j.chom.2020.05.020 · Cited by 617
A Mouse-Adapted SARS-CoV-2 Induces Acute Lung Injury and Mortality in Standard Laboratory Mice
Leist, S. R., Dinnon, K. H., Schäfer, A., Tse, L. V., Okuda, K., Hou, Y. J., West, A., Edwards, C. E., Sanders, W., Fritch, E. J., et al. (2020) · Cell · doi:10.1016/j.cell.2020.09.050 · Cited by 613
IFN-I response timing relative to virus replication determines MERS coronavirus infection outcomes
Channappanavar, R., Fehr, A. R., Zheng, J., Wohlford-Lenane, C., Abrahante, J. E., Mack, M., Sompallae, R., McCray, P. B., Meyerholz, D. K., & Perlman, S. (2019) · Journal of Clinical Investigation · doi:10.1172/jci126363 · Cited by 556
Self-citationSARS-CoV-2 Orf6 hijacks Nup98 to block STAT nuclear import and antagonize interferon signaling
Miorin, L., Kehrer, T., Sanchez-Aparicio, M. T., Zhang, K., Cohen, P., Patel, R. S., Cupic, A., Makio, T., Mei, M., Moreno, E., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2016650117 · Cited by 527
SARS-CoV-2 nsp13, nsp14, nsp15 and orf6 function as potent interferon antagonists
Yuen, C.-K., Lam, J.-Y., Wong, W.-M., Mak, L.-F., Wang, X., Chu, H., Cai, J.-P., Jin, D.-Y., To, K. K.-W., Chan, J. F.-W., et al. (2020) · Emerging Microbes & Infections · doi:10.1080/22221751.2020.1780953 · Cited by 524
Hui, K. P. Y., Cheung, M.-C., Perera, R. A. P. M., Ng, K.-C., Bui, C. H. T., Ho, J. C. W., Ng, M. M. T., Kuok, D. I. T., Shih, K. C., Tsao, S.-W., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30193-4 · Cited by 506
Galani, I.-E., Rovina, N., Lampropoulou, V., Triantafyllia, V., Manioudaki, M., Pavlos, E., Koukaki, E., Fragkou, P. C., Panou, V., Rapti, V., et al. (2021) · Nature Immunology · doi:10.1038/s41590-020-00840-x · Cited by 503
COVID-19 treatments and pathogenesis including anosmia in K18-hACE2 mice
Zheng, J., Wong, L.-Y. R., Li, K., Verma, A. K., Ortiz, M. E., Wohlford-Lenane, C., Leidinger, M. R., Knudson, C. M., Meyerholz, D. K., McCray, P. B., et al. (2021) · Nature · doi:10.1038/s41586-020-2943-z · Cited by 500
Self-citationNatural killer cell immunotypes related to COVID-19 disease severity
Maucourant, C., Filipovic, I., Ponzetta, A., Aleman, S., Cornillet, M., Hertwig, L., Strunz, B., Lentini, A., Reinius, B., Brownlie, D., et al. (2020) · Science Immunology · doi:10.1126/sciimmunol.abd6832 · Cited by 484
Type I Interferon Susceptibility Distinguishes SARS-CoV-2 from SARS-CoV
Lokugamage, K. G., Hage, A., de Vries, M., Valero-Jimenez, A. M., Schindewolf, C., Dittmann, M., Rajsbaum, R., & Menachery, V. D. (2020) · Journal of Virology · doi:10.1128/jvi.01410-20 · Cited by 483
Newton, A. H., Cardani, A., & Braciale, T. J. (2016) · Seminars in Immunopathology · doi:10.1007/s00281-016-0558-0 · Cited by 476
Cheung, C. Y., Poon, L. L. M., Ng, I. H. Y., Luk, W., Sia, S.-F., Wu, M. H. S., Chan, K.-H., Yuen, K.-Y., Gordon, S., Guan, Y., et al. (2005) · Journal of Virology · doi:10.1128/jvi.79.12.7819-7826.2005 · Cited by 461
Monk, P. D., Marsden, R. J., Tear, V. J., Brookes, J., Batten, T. N., Mankowski, M., Gabbay, F. J., Davies, D. E., Holgate, S. T., Ho, L.-P., et al. (2021) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30511-7 · Cited by 438
Konno, Y., Kimura, I., Uriu, K., Fukushi, M., Irie, T., Koyanagi, Y., Sauter, D., Gifford, R. J., Nakagawa, S., & Sato, K. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108185 · Cited by 433
Katsura, H., Sontake, V., Tata, A., Kobayashi, Y., Edwards, C. E., Heaton, B. E., Konkimalla, A., Asakura, T., Mikami, Y., Fritch, E. J., et al. (2020) · Cell Stem Cell · doi:10.1016/j.stem.2020.10.005 · Cited by 416
Lethality of SARS-CoV-2 infection in K18 human angiotensin-converting enzyme 2 transgenic mice
Oladunni, F. S., Park, J.-G., Pino, P. A., Gonzalez, O., Akhter, A., Allué-Guardia, A., Olmo-Fontánez, A., Gautam, S., Garcia-Vilanova, A., Ye, C., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19891-7 · Cited by 402
Control of coronavirus infection through plasmacytoid dendritic-cell–derived type I interferon
Cervantes-Barragan, L., Züst, R., Weber, F., Spiegel, M., Lang, K. S., Akira, S., Thiel, V., & Ludewig, B. (2007) · Blood · doi:10.1182/blood-2006-05-023770 · Cited by 397
Cameron, M. J., Ran, L., Xu, L., Danesh, A., Bermejo-Martin, J. F., Cameron, C. M., Muller, M. P., Gold, W. L., Richardson, S. E., Poutanen, S. M., et al. (2007) · Journal of Virology · doi:10.1128/jvi.00527-07 · Cited by 386
Pegylated interferon-α protects type 1 pneumocytes against SARS coronavirus infection in macaques
Haagmans, B. L., Kuiken, T., Martina, B. E., Fouchier, R. A. M., Rimmelzwaan, G. F., van Amerongen, G., van Riel, D., de Jong, T., Itamura, S., Chan, K.-H., et al. (2004) · Nature Medicine · doi:10.1038/nm1001 · Cited by 381
Zheng, Y., Zhuang, M.-W., Han, L., Zhang, J., Nan, M.-L., Zhan, P., Kang, D., Liu, X., Gao, C., & Wang, P.-H. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00438-7 · Cited by 302
Wang, N., Zhan, Y., Zhu, L., Hou, Z., Liu, F., Song, P., Qiu, F., Wang, X., Zou, X., Wan, D., et al. (2020) · Cell Host & Microbe · doi:10.1016/j.chom.2020.07.005 · Cited by 287
Mudd, P. A., Crawford, J. C., Turner, J. S., Souquette, A., Reynolds, D., Bender, D., Bosanquet, J. P., Anand, N. J., Striker, D. A., Martin, R. S., et al. (2020) · Science Advances · doi:10.1126/sciadv.abe3024 · Cited by 269
Three-dimensional human alveolar stem cell culture models reveal infection response to SARS-CoV-2
Youk, J., Kim, T., Evans, K. V., Jeong, Y.-I., Hur, Y., Hong, S. P., Kim, J. H., Yi, K., Kim, S. Y., Na, K. J., et al. (2020) · Cell Stem Cell · doi:10.1016/j.stem.2020.10.004 · Cited by 266 · cited 1×
“A similar model system showed robust ISG expression despite minimally elevated IFN-I at 72 hpi, indicating that ISG expression occurred in an IFN-I-independentmanner (Youk et al., 2020).”
MethodWu, J., Shi, Y., Pan, X., Wu, S., Hou, R., Zhang, Y., Zhong, T., Tang, H., Du, W., Wang, L., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.108761 · Cited by 265
Boudewijns, R., Thibaut, H. J., Kaptein, S. J. F., Li, R., Vergote, V., Seldeslachts, L., Van Weyenbergh, J., De Keyzer, C., Bervoets, L., Sharma, S., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19684-y · Cited by 263
Deciphering the COVID‐19 cytokine storm: Systematic review and meta‐analysis
Mulchandani, R., Lyngdoh, T., & Kakkar, A. K. (2021) · European Journal of Clinical Investigation · doi:10.1111/eci.13429 · Cited by 236
Feld, J. J., Kandel, C., Biondi, M. J., Kozak, R. A., Zahoor, M. A., Lemieux, C., Borgia, S. M., Boggild, A. K., Powis, J., McCready, J., et al. (2021) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30566-x · Cited by 236
Roth-Cross, J. K., Bender, S. J., & Weiss, S. R. (2008) · Journal of Virology · doi:10.1128/jvi.01199-08 · Cited by 227
Pathological evidence for residual SARS-CoV-2 in pulmonary tissues of a ready-for-discharge patient
Yao, X.-H., He, Z.-C., Li, T.-Y., Zhang, H.-R., Wang, Y., Mou, H., Guo, Q., Yu, S.-C., Ding, Y., Liu, X., et al. (2020) · Cell Research · doi:10.1038/s41422-020-0318-5 · Cited by 219
Mu, J., Fang, Y., Yang, Q., Shu, T., Wang, A., Huang, M., Jin, L., Deng, F., Qiu, Y., & Zhou, X. (2020) · Cell Discovery · doi:10.1038/s41421-020-00208-3 · Cited by 213
SARS-CoV-2 membrane glycoprotein M antagonizes the MAVS-mediated innate antiviral response
Fu, Y.-Z., Wang, S.-Y., Zheng, Z.-Q., Huang, Y., Li, W.-W., Xu, Z.-S., & Wang, Y.-Y. (2021) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-00571-x · Cited by 210
Responses to acute infection with SARS-CoV-2 in the lungs of rhesus macaques, baboons and marmosets
Singh, D. K., Singh, B., Ganatra, S. R., Gazi, M., Cole, J., Thippeshappa, R., Alfson, K. J., Clemmons, E., Gonzalez, O., Escobedo, R., et al. (2020) · Nature Microbiology · doi:10.1038/s41564-020-00841-4 · Cited by 209
Yang, D., Chu, H., Hou, Y., Chai, Y., Shuai, H., Lee, A. C.-Y., Zhang, X., Wang, Y., Hu, B., Huang, X., et al. (2020) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaa356 · Cited by 179
Coronavirus virulence genes with main focus on SARS-CoV envelope gene
DeDiego, M. L., Nieto-Torres, J. L., Jimenez-Guardeño, J. M., Regla-Nava, J. A., Castaño-Rodriguez, C., Fernandez-Delgado, R., Usera, F., & Enjuanes, L. (2014) · Virus Research · doi:10.1016/j.virusres.2014.07.024 · Cited by 177
Hoagland, D. A., Møller, R., Uhl, S. A., Oishi, K., Frere, J., Golynker, I., Horiuchi, S., Panis, M., Blanco-Melo, D., Sachs, D., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.01.017 · Cited by 177
Cavalli, G., Larcher, A., Tomelleri, A., Campochiaro, C., Della-Torre, E., De Luca, G., Farina, N., Boffini, N., Ruggeri, A., Poli, A., et al. (2021) · The Lancet Rheumatology · doi:10.1016/s2665-9913(21)00012-6 · Cited by 173
Zheng, J., Wang, Y., Li, K., Meyerholz, D. K., Allamargot, C., & Perlman, S. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaa753 · Cited by 158
Self-citationA distinct innate immune signature marks progression from mild to severe COVID-19
Chevrier, S., Zurbuchen, Y., Cervia, C., Adamo, S., Raeber, M. E., de Souza, N., Sivapatham, S., Jacobs, A., Bächli, E., Rudiger, A., et al. (2020) · Cell Reports Medicine · doi:10.1016/j.xcrm.2020.100166 · Cited by 157
Cell-Type-Specific Immune Dysregulation in Severely Ill COVID-19 Patients
Yao, C., Bora, S. A., Parimon, T., Zaman, T., Friedman, O., Palatinus, J. A., Surapaneni, N. S., Matusov, Y. P., Chiang, G. C., Kassar, A. G., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108590 · Cited by 155
Jagannathan, P., Andrews, J. R., Bonilla, H. F., Hedlin, H., Jacobson, K. B., Balasubramanian, V., Purington, N., Kamble, S., de Vries, C. R., Quintero, O., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22177-1 · Cited by 138
(2016) · Elsevier eBooks · doi:10.1016/c2009-1-03738-1 · Cited by 136
Lin, J., Tang, C., Wei, H.-C., Du, B., Chen, C., Wang, M., Zhou, Y., Yu, M., Cheng, L., Kuivanen, S. H., et al. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.01.015 · Cited by 132
Rashid, F., Dzakah, E. E., Wang, H., & Tang, S. (2021) · Virus Research · doi:10.1016/j.virusres.2021.198350 · Cited by 125
Zhou, H., & Perlman, S. M. (2006) · Journal of Virology · doi:10.1128/jvi.01512-06 · Cited by 124
Self-citationVersteeg, G. A., Bredenbeek, P. J., van den Worm, S. H. E., & Spaan, W. J. M. (2007) · Virology · doi:10.1016/j.virol.2007.01.020 · Cited by 121
Interferon Beta-1b and Lopinavir–Ritonavir for Middle East Respiratory Syndrome
Arabi, Y. M., Asiri, A. Y., Assiri, A. M., Balkhy, H. H., bshabshe, A. A. A. A., Jeraisy, M. A., Mandourah, Y., Azzam, M. H., Eshaq, A. M. B., Johani, S. A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2015294 · Cited by 86
Treating COVID-19 with colchicine in community healthcare setting
Della‐Torre, E., Della-Torre, F., Kusanovic, M., Scotti, R., Ramirez, G. A., Dagna, L., & Tresoldi, M. (2020) · Clinical Immunology · doi:10.1016/j.clim.2020.108490 · Cited by 84
Bessière, P., Wasniewski, M., Meyer, E. P., Servat, A., Figueroa, T., Foret, C., Coggon, A., Lesellier, S., Boué, F., Cebron, N., et al. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1009427 · Cited by 69
SARS-CoV-2 infection induces protective immunity and limits transmission in Syrian hamsters
Selvaraj, P., Lien, C. Z., Liu, S., Stauft, C. B., Nuñez, I. A., Hernández, M., Nimako, E., Ortega, M. A., Starost, M. F., Dennis, J. U., et al. (2021) · Life Science Alliance · doi:10.26508/lsa.202000886 · Cited by 49
Interferon-α2b Treatment for COVID-19 Is Associated with Improvements in Lung Abnormalities
Zhou, Q., MacArthur, M. R., He, X., Wei, X., Zarin, P., Hanna, B. S., Wang, Z.-H., Xiang, X., & Fish, E. N. (2020) · Viruses · doi:10.3390/v13010044 · Cited by 44
Low-dose ruxolitinib plus steroid in severe SARS-CoV-2 pneumonia
D’Alessio, A., Poggio, P. D., Bracchi, F., Cesana, G., Sertori, N., Mauro, D. D., Fargnoli, A., Motta, M., Giussani, C., Moro, P., et al. (2020) · Leukemia · doi:10.1038/s41375-020-01087-z · Cited by 32
Cited by
Human genetic and immunological determinants of critical COVID-19 pneumonia
Zhang, Q., Bastard, P., Effort, C. H. G., Karbuz, A., Gervais, A., Tayoun, A. A., Aiuti, A., Belot, A., Bolze, A., Gaudet, A., et al. (2022) · Nature · doi:10.1038/s41586-022-04447-0 · Cited by 366
SARS-CoV-2 spreads through cell-to-cell transmission
Zeng, C., Evans, J. P., King, T., Zheng, Y.-M., Oltz, E. M., Whelan, S. P. J., Saif, L. J., Peeples, M. E., & Liu, S.-L. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2111400119 · Cited by 246
“Low levels of neutralizing antibodies, as well as a deficiency in type I IFNs, have been reported for SARS-CoV-2 (18, 33–37) and may have contributed to the COVID-19 pandemic and disease progression (38–43).”
Bat genomes illuminate adaptations to viral tolerance and disease resistance
Morales, A. E., Dong, Y., Brown, T., Baid, K., Kontopoulos, D. G., Gonzalez, V., Huang, Z., Ahmed, A.-W., Bhuinya, A., Hilgers, L., et al. (2025) · Nature · doi:10.1038/s41586-024-08471-0 · Cited by 78
Metadata
- Authors
- Lowery, S. A., Sariol, A., & Perlman, S.
- Venue
- Cell Host & Microbe
- Publisher
- Elsevier BV
- Published
- 2021-07
- Volume
- 29
- Issue
- 7
- Pages
- 1052-1062
- ISSN
- 1931-3128 (ISSN-L)
- OpenAlex
- W3161424923
- Cited by
- 294
- References
- 87
- FWCI
- 18.07
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.